B. Riley analyst Mayank Mamtani initiated coverage of Viking Therapeutics (VKTX) with a Buy rating and $109 price target The firm has confidence in the “long-term disruptive potential” of the company’s lead program VK2735 in the “fast-expanding” obesity and type 2 diabetes metabolic dysfunction-associated steatohepatitis landscape. Viking has the only GLP1/GIP agonist being developed for an induction and maintenance paradigm, the analyst tells investors in a research note. Year to date, Viking has generated a best-in-indication oral dataset, contends Riley.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics reports results from Phase 2b clinical trial of VK2809
- Viking to present data from Phase 2b VOYAGE study in late breaker presentation
- Biotech Alert: Searches spiking for these stocks today
- Viking Therapeutics (VKTX) Stock Surges on Promising Treatment Pipeline
- Viking Therapeutics participates in a conference call with JPMorgan